The Straits Times
AsiaPac · 4 hrs ago
✦ 75✓ Factual
Lung cancer patients on drug from China’s Akeso lived longer
75Quality
0Ratings
0Comments
AI Analysis
Quality 75/100
Partisan intensity 15/100
ObjectivePartisan
Low partisan intensity — consistent with factual reporting✓ Fair headline
A clinical trial found that lung cancer patients treated with ivonescimab, a drug developed by Chinese biotech company Akeso, survived four months longer on average than those receiving standard immunotherapy.
Lung cancer patients on drug from China’s Akeso lived longer
Patients on ivonescimab lived longer by four months compared to those on immunotherapy.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!